Califf: More Expedited Approvals Mean US Clearance Only The Beginning Of Learning About Medical Products
Executive Summary
The US FDA commissioner said increased use of expedited approval pathways will help spur clinical research system reform.
You may also be interested in...
US FDA Wants To Help Sponsors Generate Evidence CMS Needs, But Won't Be An Intermediary
FDA-CMS communications are expected to evolve as both agencies look to improve their relationship.
US FDA Commissioner Califf Expects To Leave Post Following 2024 Elections
Outlining what changes he wants to see at the agency before he leaves, Califf also worries congressional inaction on the user fee reauthorization could affect hiring efforts.
Califf Appears To Set 2025 As End Of His Term As US FDA Commissioner
Outlining what changes he wants to see at the agency before he leaves, Califf also worries congressional inaction on the user fee reauthorization could affect hiring efforts.